Codex 12 capsules 5mld 250mg

  • Biocodex Sas
  • 029032075

Codex is a drug based on the active ingredient saccharomyces boulardii, belonging to the category of antidiarrheal microorganisms and specifically antidiarrheal microorganisms. Codex can be prescribed with OTC Recipe - self-medication. Prophylaxis and treatment of intestinal dysmicrobism and related diarrheal syndromes.

info_outline View product sheet
Final Price €13.90

Volume discounts

Quantity Unit discount You Save
2 10% €2.78
5 15% €10.43
10 25% €34.75
Quantity
check_circle Available
Shipped within 24 h
  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Antidiarrheals and Antispasmodics Others products at unbeatable price

Biocodex Sas

Discover all products

CODEX * 12CPS 5MLD 250MG

Therapeutic indications

Prophylaxis and treatment of intestinal dysmicrobism and related diarrheal syndromes.

Dosage and method of use

Adults: 1-2 capsules 2 times a day. Unless otherwise prescribed by a doctor. It is advisable to administer Codex at regular intervals, preferably on an empty stomach or at least 15 minutes before meals. During therapy with antibiotics, administer Codex at the same time as these. Due to the risk of airborne contamination, the capsules should not be opened in patient environments. When handling probiotics for administration to patients, healthcare professionals should wear disposable gloves, dispose of them immediately after use and wash their hands thoroughly (see section 4.4).

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with central venous catheter. Allergy to yeasts, especially aSaccharomyces boulardii. Critically ill or immunocompromised patients due to the risk of fungemia (see section 4.4).

Side effects

The following undesirable effects have been reported following administration of Codex:

Organic system classification Rare Very rare Frequency not known
Skin and subcutaneous tissue disorders   allergic reactions: face edema (angioedema), itching, hives (urticaria) and localized or systemic rash.  
Disorders of the immune system   Anaphylactic reaction or shock.  
Gastrointestinal disorders Flatulence   Constipation
Infections and infestations   Fungemia in patients with central venous catheter and in critically ill or immunocompromised patients (see section 4.4). Sepsis in critically ill or immunocompromised patients (see section 4.4)

Reporting of suspected adverse reactions.Reporting of suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

Do not mix Codex with too hot liquids or with alcoholic solutions. In view of the fungal nature ofSaccharomyces boulardii, Codex should not be administered during topical or systemic antifungal therapy. General informations - Treatment of diarrhea is not a substitute for rehydration when needed. The extent of rehydration and its route of administration should be commensurate with the severity of the diarrhea and the age and state of health of the patient. - There have been very rare cases of fungemia (and positive blood cultures forSaccharomyces) and sepsis mostly in patients with central venous catheter, critically ill or immunocompromised, resulting in most cases in pyrexia. In the majority of cases the outcome was satisfactory after discontinuation of treatment withSaccharomyces boulardii, the administration of antifungal treatment and the removal of the catheter, if necessary. However, the outcome was fatal in some critically ill patients (see sections 4.3 and 4.8). - As with all drugs based on live microorganisms, special care must be taken when handling the product, mainly in the presence of patients with a central venous catheter, but also in the presence of patients with a peripheral venous catheter, even if not treated withSaccharomyces boulardii, in order to avoid contact contamination and / or spread of microorganisms by air (see section 4.2). Important information about some of the ingredients CODEX 5 billion hard capsules- containslactose.Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine - it does not contain gluten.

Pregnancy and breastfeeding

No reliable information is available regarding teratogenicity in animals. Clinically no cases of malformations and foetotoxic effects have been reported. However, as there are insufficient data from the monitoring of pregnant women exposed to the medicinal product, all risks cannot be excluded. Despite theSaccharomyces boulardiiis not absorbed, its administration during pregnancy and during the lactation period should be carried out only in case of real need under the direct supervision of the doctor who will evaluate the risk / benefit ratio.

Expiry and retention

No special storage precautions.

Interactions with other drugs

In view of the fungal nature ofSaccharomyces boulardii, Codex should not be administered during topical or systemic antifungal therapy.

Overdose

In the event of an overdose, no special interventions are required.

Active principles

Codex 5 billion hard capsulesEach capsule contains: active ingredient:Saccharomyces boulardii5 billion live germs (in the form of 250 mg of lyophilized powder) Excipient with known effect: lactose. For the full list of excipients, see section 6.1

Excipients

Codex 5 billion hard capsulesEach capsule contains: lactose; magnesium stearate; jelly; titanium dioxide

Biocodex Sas
029032075

Data sheet

Packaging
5 billion 12 hard capsules
Product Type
HUMAN DRUG
ATC code
A07FA02
ATC description
Saccharomyces boulardii
Therapeutic Group
Antidiarrheal microorganisms
Active principle
saccharomyces boulardii
Class
C.
Pharmaceutical form
capsule
Type of Administration
oral
Container
blister
Quantity
12 capsule
Quantity of the Active Ingredient
250MG
Recipe required
OTC - self-medication medicine
chat Comments (0)
Fast Order